Recent Updates
Recently added Catalysts

Comparator: V505 formulation 1

Phase 2

Cervical Cancer | Monoclonal antibody | Oncology |Merck & Company, Inc.|Last Updated: Nov 26, 2015

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindACTIVE_CONTROLLEDDMC
Total Trials1
Total Enrollment511
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00520598Broad Spectrum HPV (Human Papillomavirus) Vaccine in 16 to 26 Year Old Women (V505-001)PHASE2 COMPLETED 511Oct 1, 2007May 1, 2011Nov 26, 2015 -
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Geometric mean titers (GMTs) to HPV types contained in the vaccines administered in a 3-dose regimen
4 weeks post dose 3
Secondary Endpoints
Geometric mean titers (GMTs) to HPV types contained in the vaccines administered in a 2-dose regimen
4 weeks post dose 2
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposePREVENTION
Treatment Arms
ArmTypeDescription
1ACTIVE_COMPARATORArm 1: 0.5 ml injection of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine as 3 dose regimen.
2EXPERIMENTALArm 2: 0.5 ml injection of V505 formulation 1 as 3 dose regimen.
3EXPERIMENTALArm 3: 0.5 ml injection of V505 formulation 2 as 3 dose regimen
4EXPERIMENTALArm 4: 0.5 ml injection of V505 formulation 2 as 2 dose regimen and 1 Pbo injection
5EXPERIMENTALArm 5: 0.5 ml injection of V505 formulation 3 as 2 dose regimen and 1 Pbo injection
Interventions
NameTypeDescription
Comparator: V505 formulation 1BIOLOGICAL0.5 ml injection of V505 formulation 1 as 3 dose regimen at Day 1, Month 2 and Month 6.
Comparator: V505 formulation 2DRUG0.5 ml injection of V505 formulation 2 as 3 dose regimen at Day 1, Month 2 and Month 6.
Comparator: V505 formulation 3BIOLOGICAL0.5 ml injection of V505 formulation 3 as 2 dose regimen at Day 1 and Month 6.
Comparator: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) RecombinantBIOLOGICAL0.5 ml injection of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine as 3 dose regimen at Day 1, Month 2 and Month 6.
Comparator: Placebo (unspecified)BIOLOGICAL0.5 ml injection of placebo to V505 as a 1 dose regimen at Month 2.
Unlock Study Design Details
Eligibility Criteria
Age Range16 Years — 26 Years
SexFEMALE
Healthy VolunteersYes

Inclusion Criteria: * Female between 16 to 26 years old * Has never had Pap testing or have only had normal Pap test results * Lifetime history of 0 to 4 sexual partners Exclusion Criteria: * History of an abnormal cervical biopsy result; History of a positive test for HPV; History of external ge...

Unlock Eligibility Criteria
Competitive Landscape -Cervical Cancer 68 trials
CompanyTickerTrialsLead PhaseDrugs
AstraZeneca PLCAZN5PHASE3Volrustomig, Cisplatin, Carboplatin, Paclitaxel, 5-FU
Merck & Co., Inc.MRK4PHASE3Sacituzumab Tirumotecan, Pemetrexed, Tisotumab Vedotin, Topotecan, Vinorelbine
Pfizer Inc.PFE3PHASE2tucatinib, trastuzumab, fulvestrant, TG4001, Avelumab
ImmunityBio IncIBRX2PHASE2N-803 + Pembrolizumab, IBRX-042
Eli Lilly and CompanyLLY3PHASE1LY4101174, LY4052031, LY4170156, bevacizumab, carboplatin
MacroGenics, Inc.MGNX2PHASE2Lorigerlimab, MGC026 Dose Escalation
Precigen IncPGEN1PHASE2PRGN-2009 plus Pembrolizumab
Xencor, Inc.XNCR1PHASE2vudalimab
Incyte CorporationINCY1PHASE2Chemotherapy, Retifanlimab
Iovance Biotherapeutics IncIOVA3PHASE2E7 TCR-T cells, Aldesleukin, KK-LC-1 TCR-T cells
Bristol-Myers Squibb CompanyBMY1PHASE1BMS-986340, BMS-936558-01, Docetaxel, Pumitamig
AbbVie, Inc.ABBV1PHASE1IMGN151
Arcus Biosciences, Inc.RCUS1PHASE1AB598, Zimberelimab, Fluorouracil, Leucovorin, Oxaliplatin
Ascendis Pharma A/SASND1PHASE1TransCon IL-2 β/γ, Pembrolizumab, Chemotherapy drug, TransCon TLR7/8 Agonist, Trastuzumab
Nanobiotix SA Sponsored ADRNBTX1PHASE1NBTXR3, Nivolumab, Pembrolizumab
TScan Therapeutics, Inc.TCRX2PHASE1TSC-204-A0201, TSC-204-C0702, TSC-200-A0201, TSC-203-A0201, TSC-204-A0101
Oncolytics Biotech Inc.ONCY1PHASE1Pelareorep, Atezolizumab, Gemcitabine and nab-paclitaxel, Trifluridine Tipiracil, mFOLFIRINOX Treatment Regimen
Adlai Nortye Ltd. Sponsored ADRANL1PHASE1AN0025, Pembrolizumab
Nurix Therapeutics, Inc.NRIX1PHASE1NX-1607, Paclitaxel
Boundless Bio Inc.BOLD1PHASE1BBI-355, Erlotinib, Futibatinib, BBI-825
Unlock Competitive Intelligence